As an irreversible inhibitor of the ErbB family of tyrosine kinases, the second-generation TKIs afatinib is a valuable option for patients with advanced lung adenocarcinoma harboring activating EGFR mutations37. Here, EGFR is linked to lung adenocarcinoma.